Moteur de recherche d’entreprises européennes
Financement de l’UE (10,1 M €) : L’immunothérapie personnalisée dans le sepsis : une approche basée sur la médecine de précision Hor01/01/2020 Programme de recherche et d'innovation de l'UE « Horizon »
Texte
L’immunothérapie personnalisée dans le sepsis : une approche basée sur la médecine de précision
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection, and is characterized by a high mortality of up to 30-40%. Treatment of sepsis was revolutionized by two steps that significantly decreased mortality: antibiotics and the intensive care units. It has been hoped that a third revolution, immunotherapy, would further improve outcome of sepsis, but this hope did not materialize. This was due to the incompletely understood pathophysiology, and the heterogeneity of the immune status in different sepsis patients. We propose that while both overinflammation and immunoparalysis are important, they are present in individual sepsis patients.The mission of the present project is to design and perform a proof-of-concept clinical trial of personalized immunotherapy in sepsis, and within this clinical trial, to develop a next-generation theranostics platform for the design of future personalized immunotherapy trials in sepsis. This theranostics platform would be based on an integrated, multidimensional systems biology analysis of omics-based datasets, to identify biomarkers, clinical endotypes, and therapeutic targets for precision medicine approaches. In order to achieve the mission proposed, several complementary aims will be pursued: Aim 1: To design and perform a large personalized immunotherapy trial in sepsis patients, that can provide a clinical answer towards the usefulness of currently employed immunotherapies for sepsis. Aim 2: To chart host genome, epigenome, transcriptome, metabolome and microbiome in at least 180 sepsis patients enrolled in Aim 1 over a defined time course. Aim 3: To use a theranostics approach based on the data provided by Aim 2 to design novel personalized immunotherapeutic strategies. Aim 4: To integrate the clinical and psychological aspects involved when introducing novel immunotherapies for infections in the health care systems of European countries, building bridges with the patient community.
| Bioaster Fondation de Cooperation Scientifique | 457 078 € |
| Biomerieux SA | 399 685 € |
| Cemm - Forschungszentrum Fuer Molekulare Medizin GmbH | 480 965 € |
| Centre Hospitalier Universitaire Vaudois | 709 990 € |
| Elliniko Instituto Meletis TIS Sipsis | 2 397 500 € |
| Eurice European Research AND Project Office GmbH | 402 625 € |
| Hospices Civils de Lyon | 336 132 € |
| Rheinische Friedrich-Wilhelms-Universitat Bonn | 505 881 € |
| Stichting Amsterdam UMC | 900 087 € |
| Stichting Radboud Universitair Medisch Centrum | 1 620 266 € |
| Stichting Radboud Universiteit | 0,00 € |
| TEL Aviv University | 399 975 € |
| The University of Reading | 387 000 € |
| Universitatea de Medicina si Farmacie Iuliu Hatieganu Cluj-Napoca | 399 275 € |
| Universitatsklinikum Jena | 684 875 € |
https://cordis.europa.eu/project/id/847422
Cette annonce se réfère à une date antérieure et ne reflète pas nécessairement l’état actuel.
